LeadArt Biotechnologies Completes US$6M Pre-A Financing
- LeadArt Biotechnologies, a Boston, MA and Ningbo, China-based biotechnology company focused on drug discovery by automating chemoproteomics processes, raised US$6M in Pre-A funding
- The round was led by BlueRun Ventures Aster
- The company intends to use the funds to advance the development of its automated chemoproteomics platform and the creation of a human target-probe database
- LeadArtBiotechnologies is accelerating drug discovery by automating chemoproteomics processes and creating a human live-cell target-probe database
- Its platform integrates biotechnology and automation technologies to discover disease-related targets and chemical probes for traditionally undruggable and unexplored targets.
